Un estudio para investigar la eficacia y la seguridad de SAR441566 en pacientes con colitis ulcerosa (SPECIFI-UC)
Un estudio de fase 2, multinacional, multicéntrico, aleatorizado, doble ciego, controlado con placebo, que alcanza la dosis para evaluar la eficacia y la seguridad de SAR441566 en adultos con colitis ulcerosa moderada a severa
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.
Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).
- The study duration will be up to 59 weeks.
- The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
- The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Investigational Site Number : 2760005
-
Berlin, Alemania, 14050
- Investigational Site Number : 2760008
-
Duisburg, Alemania, 47055
- Investigational Site Number : 2760010
-
Frankfurt, Alemania, 60590
- Investigational Site Number : 2760009
-
Hanover, Alemania, 30625
- Investigational Site Number : 2760003
-
Tübingen, Alemania, 72076
- Investigational Site Number : 2760011
-
Ulm, Alemania, 89081
- Investigational Site Number : 2760006
-
-
-
-
-
Buenos Aires, Argentina, 1061
- Investigational Site Number : 0320001
-
Buenos Aires, Argentina, 1006
- Investigational Site Number : 0320003
-
Buenos Aires, Argentina, 1023
- Investigational Site Number : 0320002
-
Buenos Aires, Argentina, 1125
- Investigational Site Number : 0320005
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentina, 4000
- Investigational Site Number : 0320004
-
-
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Investigational Site Number : 0360003
-
-
Victoria
-
Richmond, Victoria, Australia, 3121
- Investigational Site Number : 0360005
-
-
-
-
-
Salzburg, Austria, 5020
- Investigational Site Number : 0400002
-
Vienna, Austria, 1090
- Investigational Site Number : 0400001
-
-
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035903
- Hospital de Clinicas de Porto Alegre- Site Number : 0760002
-
Porto Alegre, Rio Grande do Sul, Brasil, 90160-093
- Hospital Ernesto Dornelles- Site Number : 0760003
-
-
-
-
-
Burgas, Bulgaria, 8000
- Investigational Site Number : 1000001
-
Rousse, Bulgaria, 7002
- Investigational Site Number : 1000003
-
Sofia, Bulgaria, 1612
- Investigational Site Number : 1000002
-
-
-
-
-
Ghent, Bélgica, 9000
- Investigational Site Number : 0560002
-
Leuven, Bélgica, 3000
- Investigational Site Number : 0560001
-
-
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canadá, B4N 0A3
- Investigational Site Number : 1240004
-
-
Ontario
-
Ajax, Ontario, Canadá, L1S 7K7
- Investigational Site Number : 1240006
-
Richmond Hill, Ontario, Canadá, L4C 9M7
- Investigational Site Number : 1240005
-
-
Quebec
-
Québec, Quebec, Canadá, G1N 4V3
- Investigational Site Number : 1240001
-
-
-
-
-
Olomouc, Chequia, 779 00
- Investigational Site Number : 2030001
-
Ostrava, Chequia, 710 00
- Investigational Site Number : 2030002
-
-
-
-
Reg Metropolitana de Santiago
-
Santiago, Reg Metropolitana de Santiago, Chile, 8330034
- Investigational Site Number : 1520003
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500010
- Investigational Site Number : 1520002
-
Santiago, Reg Metropolitana de Santiago, Chile, 8331143
- Investigational Site Number : 1520001
-
-
-
-
-
Osijek, Croacia, 31000
- Investigational Site Number : 1910001
-
-
-
-
Arizona
-
Sun City, Arizona, Estados Unidos, 85351
- GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003
-
-
Connecticut
-
Bristol, Connecticut, Estados Unidos, 06010
- Bristol Hospital- Site Number : 8400017
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Novum Research- Site Number : 8400018
-
Kissimmee, Florida, Estados Unidos, 34741
- Clinical Research of Osceola- Site Number : 8400012
-
Miami Lakes, Florida, Estados Unidos, 33016
- Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002
-
Tampa, Florida, Estados Unidos, 33609
- GCP Clinical Research- Site Number : 8400016
-
-
Illinois
-
Glenview, Illinois, Estados Unidos, 60026
- GI Alliance - Glenview- Site Number : 8400005
-
Gurnee, Illinois, Estados Unidos, 60031
- Illinois Gastroenterology Group- Site Number : 8400004
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400010
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai- Site Number : 8400001
-
Queens Village, New York, Estados Unidos, 11428
- Queens Village Primary Medical Center- Site Number : 8400011
-
-
Ohio
-
Lima, Ohio, Estados Unidos, 45805
- NexGen Research- Site Number : 8400020
-
-
Pennsylvania
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- Frontier Clinical Research - Uniontown- Site Number : 8400006
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29401
- Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008
-
-
Texas
-
Katy, Texas, Estados Unidos, 77494
- Gastro Health & Nutrition- Site Number : 8400007
-
Lubbock, Texas, Estados Unidos, 79424
- SI Research Associates- Site Number : 8400019
-
Southlake, Texas, Estados Unidos, 76092
- Texas Digestive Disease Consultants - Southlake- Site Number : 8400015
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center- Site Number : 8400014
-
Tacoma, Washington, Estados Unidos, 98405
- Washington Gastroenterology - Tacoma- Site Number : 8400009
-
-
-
-
-
Nice, Francia, 06202
- Investigational Site Number : 2500003
-
Toulouse, Francia, 31059
- Investigational Site Number : 2500001
-
Vandœuvre-lès-Nancy, Francia, 54511
- Investigational Site Number : 2500002
-
-
-
-
-
Tbilisi, Georgia, 0160
- Investigational Site Number : 2680003
-
Tbilisi, Georgia, 0144
- Investigational Site Number : 2680002
-
Tbilisi, Georgia, 0180
- Investigational Site Number : 2680001
-
-
-
-
-
Athens, Grecia, 124 62
- Investigational Site Number : 3000003
-
Athens, Grecia, 106 76
- Investigational Site Number : 3000001
-
Heraklion, Grecia, 711 10
- Investigational Site Number : 3000002
-
-
-
-
-
Budapest, Hungría
- Investigational Site Number : 3480001
-
-
-
-
-
Hyderabad, India, 500082
- Investigational Site Number : 3560005
-
Jaipur, India, 302001
- Investigational Site Number : 3560003
-
Jaipur, India, 302004
- Investigational Site Number : 3560009
-
Kolkata, India, 700020
- Investigational Site Number : 3560002
-
Ludhiana, India, 141002
- Investigational Site Number : 3560004
-
Secunderabad, India, 500003
- Investigational Site Number : 3560007
-
Surat, India, 395002
- Investigational Site Number : 3560001
-
Visakhapatnam, India, 530040
- Investigational Site Number : 3560010
-
-
-
-
-
Alessandria, Italia, 15100
- Investigational Site Number : 3800007
-
Palermo, Italia, 90127
- Investigational Site Number : 3800009
-
Pisa, Italia, 56124
- Investigational Site Number : 3800004
-
-
Genova
-
Genoa, Genova, Italia, 16132
- Investigational Site Number : 3800006
-
-
Milano
-
Milan, Milano, Italia, 20132
- Investigational Site Number : 3800002
-
Rozzano, Milano, Italia, 20089
- Investigational Site Number : 3800003
-
-
Napoli
-
Naples, Napoli, Italia, 80131
- Investigational Site Number : 3800008
-
-
Padova
-
Padua, Padova, Italia, 35128
- Investigational Site Number : 3800001
-
-
Roma
-
Rome, Roma, Italia, 00161
- Investigational Site Number : 3800011
-
-
Torino
-
Turin, Torino, Italia, 10126
- Investigational Site Number : 3800010
-
-
-
-
-
Hiroshima, Japón, 734-8530
- Investigational Site Number : 3920012
-
Kagoshima, Japón, 892-0843
- Investigational Site Number : 3920016
-
Niigata, Japón, 950-1104
- Investigational Site Number : 3920001
-
Osaka, Japón, 530-0011
- Investigational Site Number : 3920010
-
Tokyo, Japón, 108-8642
- Investigational Site Number : 3920015
-
-
Chiba
-
Kashiwa, Chiba, Japón, 277-0871
- Investigational Site Number : 3920005
-
-
Hiroshima
-
Kure, Hiroshima, Japón, 737-0811
- Investigational Site Number : 3920014
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 004-0041
- Investigational Site Number : 3920003
-
Sapporo, Hokkaido, Japón, 065-0033
- Investigational Site Number : 3920007
-
-
Iwate
-
Yahaba, Iwate, Japón, 028-3695
- Investigational Site Number : 3920009
-
-
Kanagawa
-
Yokohama, Kanagawa, Japón, 220-0041
- Investigational Site Number : 3920013
-
-
Tokyo
-
Bunkyo-Ku, Tokyo, Japón, 113-8510
- Investigational Site Number : 3920002
-
Kodaira, Tokyo, Japón, 187-8510
- Investigational Site Number : 3920011
-
-
Yamanashi
-
Kofu, Yamanashi, Japón, 400-0027
- Investigational Site Number : 3920006
-
-
-
-
Lesser Poland Voivodeship
-
Oświęcim, Lesser Poland Voivodeship, Polonia, 32-600
- Investigational Site Number : 6160008
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polonia, 53-034
- Investigational Site Number : 6160005
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 03-580
- Investigational Site Number : 6160004
-
Warsaw, Masovian Voivodeship, Polonia, 04-501
- Investigational Site Number : 6160001
-
-
Podkarpackie Voivodeship
-
Rzeszów, Podkarpackie Voivodeship, Polonia, 35-055
- Investigational Site Number : 6160002
-
-
-
-
-
Guangzhou, Porcelana, 510655
- Investigational Site Number : 1560002
-
Hangzhou, Porcelana, 310016
- Investigational Site Number : 1560001
-
Huizhou, Porcelana, 516001
- Investigational Site Number : 1560003
-
Huizhou, Porcelana, 516001
- Investigational Site Number : 1560017
-
Jiazhuang, Porcelana, 050000
- Investigational Site Number : 1560004
-
Linhai, Porcelana, 317000
- Investigational Site Number : 1560014
-
Luoyang, Porcelana, 471003
- Investigational Site Number : 1560008
-
Shanghai, Porcelana, 200120
- Investigational Site Number : 1560005
-
Wuhan, Porcelana, 430014
- Investigational Site Number : 1560011
-
-
-
-
-
Constanța, Rumania, 900673
- Investigational Site Number : 6420001
-
-
-
-
-
Cape Town, Sudáfrica, 7405
- Investigational Site Number : 7100002
-
Cape Town, Sudáfrica, 7708
- Investigational Site Number : 7100001
-
KwaDukuza, Sudáfrica, 4449
- Investigational Site Number : 7100004
-
Pretoria, Sudáfrica, 0157
- Investigational Site Number : 7100005
-
Pretoria, Sudáfrica, 0002
- Investigational Site Number : 7100003
-
-
-
-
-
Istanbul, Turquía (Türkiye), 34899
- Investigational Site Number : 7920002
-
Izmir, Turquía (Türkiye), 35100
- Investigational Site Number : 7920003
-
Mersin, Turquía (Türkiye), 33070
- Investigational Site Number : 7920001
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Male or female participants aged 18 to 75 years inclusive, at the time of signing the informed consent
-
Participants who have clinical evidence of active UC for ≥3 months before screening and confirmed by endoscopy during the screening period
-
Active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician global Assessment (PGA), with a minimum rectal bleeding (RB) subscore ≥1, a minimum stool frequency (SF) subscore ≥1, a mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a disease extent >15 cm from the anal verge
-
Must have received prior treatment for UC (either "a" or "b" below or a combination of both "a" and "b"):
- History of no prior exposure to approved Advanced Therapy (AT), but having inadequate response to, loss of response to or intolerance to standard treatment with any of the following : 5-ASA, thiopurines (eg.6-MP, AZA), MTX, oral or intravenous (IV) corticosteroids or history of corticosteroid dependence (defined an inability to successfully taper corticosteroids without recurrence of UC) OR
- History of inadequate response to, loss of response to or intolerance to treatment with ≥1 approved AT such as a biologic agent (eg. TNF antagonists, anti-integrin other than natalizumab, anti-IL-12/23, anti-IL-23, or a small molecule (such as a JAKi or S1PRm) for UC
-
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participants with active CD, indeterminate colitis, ischemic colitis, microscopic colitis
- Participants with the following ongoing known complications of UC: fulminant colitis, toxic megacolon, or any other manifestation that might require bowel surgery while enrolled in the study
- Participant with prior colectomy, ostomy or ileoanal pouch, or anticipated colectomy during their participation in the study
- Participants with fecal sample positive for ova or parasites, bacterial pathogens, or positive for Clostridium difficile B toxin in stools
- Participants with active tuberculosis (TB) or a history of incompletely treated active TB or latent TB infection per local guidelines
- Participants with Positive Hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) and/or hepatitis C virus antibody (HCVAb) at the screening visit
- Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
- Participants with a known history of human immunodeficiency virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
- Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
- History of gastro-intestinal dysplasia other than completely removed low grade dysplasia OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during endoscopy by the time of the screening visit.
- If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on biopsies will be excluded.
- Female participants who is pregnant, breastfeeding, or is considering becoming pregnant during the study or within 3 months after the last dose of study drug
- Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the screening visit or oral/intramuscular anti-infectives within 14 days prior to the screening visit
- Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
- Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
- Participants who received fecal microbial transplantation within 30 days prior to screening
- Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
- Participants who received IV corticosteroids within 14 days prior to screening or during screening period
- Screening laboratory and other analyses show abnormal results.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: SAR441566 dose regimen 1
Participants will receive SAR441566 dose regimen 1 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Experimental: SAR441566 dose regimen 2
Participants will receive SAR441566 dose regimen 2 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Experimental: SAR441566 dose regimen 3
Participants will receive SAR441566 dose regimen 3 |
Pharmaceutical form: Tablet Route of administration: Oral |
|
Comparador de placebos: Placebo
Participants will receive SAR441566-matching placebo |
Pharmaceutical form: Tablet Route of administration: Oral |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)
Periodo de tiempo: Week 12
|
Clinical remission by modified Mayo score (mMS) is defined as a mMS ≤2 with no subscore >1 (stool frequency [SF] of 0 or 1 with at least a 1-point decrease from baseline, rectal bleeding [RB] of 0 and modified Mayo Endoscopic Subscore [mMES] of 0 or 1 where 1 does not include friability). Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity. |
Week 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Plasma predose concentraciones de SAR441566 en visitas seleccionadas
Periodo de tiempo: Hasta la semana 52
|
Hasta la semana 52
|
|
|
Concentraciones de plasma posterior a la dosis de SAR441566 en visitas seleccionadas
Periodo de tiempo: Hasta la semana 52
|
Hasta la semana 52
|
|
|
Número de participantes con cualquier evento adverso emergente de tratamiento (TEAES) durante el período de tratamiento de inducción y mantenimiento
Periodo de tiempo: Hasta la semana 52
|
Hasta la semana 52
|
|
|
Número de participantes con eventos adversos emergentes (TEAE) de tratamiento con tratamiento durante el período de tratamiento abierto
Periodo de tiempo: De la semana 12 a la semana 52
|
De la semana 12 a la semana 52
|
|
|
Proportion of participants achieving clinical response at Week 12 by modified Mayo Score (mMS)
Periodo de tiempo: Week 12
|
Clinical response by modified Mayo score (mMS) is defined as a decrease from baseline in the mMS of ≥2 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity. |
Week 12
|
|
Proportion of participants achieving clinical response at Week 12 by full Mayo score (MS)
Periodo de tiempo: Week 12
|
Clinical response by full Mayo score (MS) is defined as a decrease from baseline in the MS of ≥3 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. The MS (also referred to as the full Mayo Score) is a composite index designed to measure ulcerative colitis (UC) disease activity and consists of 4 subscores: RB and SF, which are patient-reported subscores, Physician's global assessment (PGA), and endoscopic findings. Individual items are rated 0 to 3, giving the composite score a maximum of 12, with higher scores indicating greater disease severity. |
Week 12
|
|
Proportion of participants achieving clinical remission at Week 12 by full Mayo score (MS)
Periodo de tiempo: Week 12
|
Clinical remission by full Mayo score (MS) is defined as a MS ≤2 with no score >1. |
Week 12
|
|
Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12
Periodo de tiempo: Week 12
|
Patient-reported outcome 2 (PRO2) remission is defined as PRO2 score ≤1 with rectal bleeding (RB) of 0, and endoscopic remission is defined as mMES of 0. PRO2 score is defined as the sum of Mayo SF and RB subscores. |
Week 12
|
|
Proportion of participants achieving endoscopic remission at Week 12
Periodo de tiempo: Week 12
|
Endoscopic remission is defined as mMES of 0. |
Week 12
|
|
Change from baseline in PRO2 from randomization to Week 12
Periodo de tiempo: From Baseline to Week 12
|
PRO2 score is defined as the sum of the Mayo SF and RB subscores. |
From Baseline to Week 12
|
|
Proportion of participants achieving endoscopic response at Week 12
Periodo de tiempo: Week 12
|
Endoscopic response is defined as mMES decrease of at least 1 point. |
Week 12
|
|
Proportion of participants achieving endoscopic improvement at Week 12
Periodo de tiempo: Week 12
|
Endoscopic improvement is defined as mMES of 0 or 1 where 1 does not include friability. |
Week 12
|
|
Proportion of participants achieving HEMI at Week 12
Periodo de tiempo: Week 12
|
Histologic endoscopic mucosal improvement (HEMI) is defined by achievement of modified Mayo endoscopic improvement (mMES of 0 or 1 where 1 does not include friability) and histological improvement (original Geboes Score [OGS] ≤3.1). |
Week 12
|
|
Proportion achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 12
Periodo de tiempo: Week 12
|
Inflammatory Bowel Disease Questionnaire (IBDQ) remission is considered as an IBDQ-32 total score ≥170 points. IBDQ is designed to capture the patient's experience of IBD on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The total IBDQ score ranges from 32 to 224 which indicates better quality of life. |
Week 12
|
|
Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 12
Periodo de tiempo: Week 12
|
Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points. |
Week 12
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- DRI17822
- U1111-1308-9729 (Otro identificador: WHO)
- 2025-520705-12 (Identificador de registro: CTIS)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .